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ABSTRACT
Objective: This study describes a new, simple, precise, accurate, and reproducible reversed-phase high-performance liquid chromatography 
(RP-HPLC) cleaning validation method for simultaneous estimation of rosuvastatin and aspirin.
Methods: The proposed RP-HPLC method was carried out on AGILENT-ZORBAX RP-Inertsil column (250 mm × 4.6 mm, 5 µm) in an isocratic mode 
utilizing potassium dihydrogen phosphate buffer (pH 2.5 with OPA):acetonitrile (50:50,v/v) as mobile phase, at a flow rate of 1.5 ml/min. Detection 
was carried out at 243 nm using UV detector.
Results: The method was found specific as there was no swab interference. The Beer–Lambert’s law was obeyed in the concentration range of 
0.5–20 µg/ml for both rosuvastatin and aspirin. The mean percentage recoveries at 100% level were 89.4% for rosuvastatin and 82.1% for aspirin. 
The limit of detection and limit of quantification for rosuvastatin and aspirin were 0.03 µg/ml and 0.1 µg/ml, respectively. The method was found to 
be robust and precise with percentage RSD <2.0%.
Conclusion: A simple, novel, and economical RP-HPLC method for cleaning validation has been developed for the simultaneous estimation of 
rosuvastatin and aspirin. The method was validated as per ICH guidelines for specificity, linearity, accuracy, precision, and robustness. The developed 
method can be used as a sensitive analytical tool for ensuring the effectiveness of the cleaning procedure adopted.
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INTRODUCTION
Rosuvastatin (Fig. 1) is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitor. It acts in the liver. Chemically, rosuvastatin is 
(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-
6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid. It 
is a statin with antilipidemic and potential antineoplastic activities. 
It selectively and competitively binds to and inhibits hepatic 
hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the 
enzyme which catalyzes the conversion of HMG-CoA to mevalonate, 
which is a precursor of cholesterol. This leads to a decrease in hepatic 
cholesterol levels and increase in uptake of LDL cholesterol [1,2].
Aspirin (Fig. 2) is an anticoagulant agent. Chemically, it is 2-acetobenzoic 
acid. It blocks the production of prostaglandins by inhibiting cyclooxygenase 
(prostaglandin H synthase), with greater selectivity toward the COX-
1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in 
platelets that block thromboxane production and platelet aggregation. It is 
chemopreventive against colorectal and other solid tumors [1,2].
Equipment contamination may come from any of the materials that 
have been in contact with the equipment surfaces. It is critical to avoid 
carryover of the trace amounts of either active or other materials from 
one batch to another to avoid cross-contamination of the subsequent 
product. Hence, equipment used in pharmaceutical manufacturing 
must be cleaned meticulously and the cleaning procedure used must 
be validated [3,4].
Literature survey reveals that many HPLC and UV methods have been 
reported for the determination of rosuvastatin and aspirin, either alone 
or in combination [5-19]. However, no method has been reported for 
cleaning validation for rosuvastatin and aspirin in combination.
Cleaning validation is required in the pharmaceutical field to 
avoid potential, clinically significant synergistic interactions 
between pharmacologically active chemicals. The objective of the 
determination of the residue of drugs during cleaning validation 
is to verify the effectiveness of the cleaning procedure for the 
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Fig. 1: Rosuvastatin
 Fig. 2: Aspirin
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removal of product residues, degradation products, preservatives, 
excipients, and/or cleaning agents as well as the control of potential 
microbial contaminants. In addition, it is needed to ensure that 
there is no risk associated with cross-contamination of active 
ingredients [20,21].
Hence, it was thought worthwhile to develop a cleaning validation HPLC 
method for the simultaneous determination of rosuvastatin calcium 
and aspirin and validate it as per ICH guidelines.
METHODS
The active pharmaceutical ingredients rosuvastatin and aspirin were 
supplied as gift samples by Vergo Pharma Research Laboratories, 
Verna, Goa. Water used for analysis was Milli Q water. Other chemicals 
used were of analytical/HPLC grade.
The HPLC system used was Agilent-Zorbax RP with a UV detector. 
Processing was done using Openlab software. The column used was 
Inertsil (250 mm × 4.6 mm, 5 µm). The mobile phase consisted of 
pH 2.5 phosphate buffer:acetonitrile (50:50, v/v). The flow rate was 
1.5 ml/min. Injection volume was 25 µl and ultraviolet detection 
wavelength was set at 243 nm.
Preparation of orthophosphoric acid (OPA)
The OPA was prepared by dissolving 1 g of OPA in 1000 ml of water. It 
was stirred well by adjusting the pH with KOH solution to get pH 2.5 
using digital pH meter.
Blank/diluent
The blank/diluent consisted of methanol:OPA adjusted to pH 2.5 with 
KOH (80:20, v/v).
Preparation of KH2PO4 buffer pH 2.5
Preparation of the buffer was carried out by dissolving 1.36 g of KH2PO4 
in 1000 ml of water. It was stirred well and the pH was adjusted to 2.5 
using OPA and filtered.
Preparation of mobile phase
The mobile phase was prepared by adding 500 ml of ACN and 500 ml of 
previously prepared KH2PO4 buffer pH 2.5 in a 1000 ml flask. Further, it 
was sonicated for 10 min.
Preparation of the standard stock solution of aspirin and 
rosuvastatin (10 ppm)
About 20 mg of aspirin and rosuvastatin each were weighed accurately 
and transferred into two separate 200 ml volumetric flask. About 30 ml 
of diluent was added and sonicated for 5 min and diluted up to the mark 
with 170 ml diluent and mixed well. Further, 10 ml of each solution was 
pipetted into two separate 100 ml volumetric flask and 30 ml of diluent 
was added and sonicated for 5 min and diluted up to the mark with 
60 ml diluent and mixed well.
Preparation of mixed standard solution (1 ppm)
About 1 ml from each standard stock solution of rosuvastatin and 
aspirin were taken and transferred to 10 ml volumetric flask and the 
volume was made up with diluent.
Method validation
The method validation was performed according to ICH 
guidelines [22,23].
System suitability
To evaluate system suitability, the mixed drug standard solution was 
injected 6 times in the HPLC system. The system suitability was then 
established by calculating the percentage RSD, resolution, tailing factor, 
and the number of theoretical plates.
Specificity
Swabs used to evaluate the specificity (swab interference) for the 
proposed method were pretreated by transferring swab sticks in a 
clean test tube containing 10 ml of diluent and sonicated for 5 min and 
then drained. The whole procedure was repeated in water and then 
back in diluent. Two pretreated swabs were then taken and put in two 
separate test tubes containing 10 ml of diluent and sonicated for about 
5 min with intermittent shaking. For the study of specificity, the two 
prepared swab solutions were injected into the HPLC system.
Linearity
To evaluate the linearity of the proposed method, a 10 ppm solution of 
rosuvastatin and aspirin was prepared by taking 10 ml of aspirin and 
10 ml of rosuvastatin (100 ppm stock solution) and diluting to 100 ml 
using diluent. The concentration range selected was 0.1–20 ppm. The 
solutions for linearity study were injected in the HPLC system and the 
linearity range was determined by plotting calibration curves for both 
the drugs. The linear regression equation and correlation coefficient (r2) 
were calculated.
Accuracy
To evaluate the accuracy of the method, recovery study was performed 
at 100% level concentration of the drugs. A 10 ppm solution of the 
drugs was prepared by taking 10 ml each of 100 ppm stock solution 
of rosuvastatin and aspirin and diluting to 100 ml using diluent. For 
recovery at 100% level, 1 ml of rosuvastatin and aspirin 10 ppm 
solution was dispersed over 4” × 4” stainless steel plate and dried using 
an electric fan. After drying, the plate was swabbed and the swabbed 
samples were collected in a test tube containing 10 ml of diluent, 
mixed, and sonicated for about 5 min with intermittent shaking to 
result in approximate 1 ppm solution. The procedure was performed 
in triplicate to result in three samples which were then injected as per 
test method and mean percentage recovery for both the drugs was 
calculated.
Precision
The evaluation of precision was done by injecting six replicates 
of rosuvastatin and aspirin mixed standard solution at limit of 
quantification (LOQ) level. The peak areas were recorded and the 
relative standard deviation for rosuvastatin and aspirin was calculated.
Limit of detection (LOD) and LOQ
The evaluation of the LOD and LOQ of rosuvastatin and aspirin was 
done based on “signal-to-noise ratio” method. The concentration which 
gave a signal-to-noise ratio of about 3 for LOD and about 10 for LOQ 
was derived. The LOD and LOQ tests were carried out using 0.1 ppm 
solution.
Robustness
The robustness for the developed method was demonstrated by 
bringing about small deliberate changes in organic phase composition, 
flow rate, pH of buffer in mobile phase, and column temperature and 
calculating its impact on system suitability parameters.
RESULTS
Table 1: System suitability parameters
System suitability 
parameters
Observed value Acceptance 
valueRosuvastatin Aspirin
%RSD (n=6) 1.01 0.84 NMT 2.0%
Average of theoretical plates 8525 8466.16 NLT 2000
Average of tailing factor 1.10 1.13 NMT 2.0
Resolution 10 NLT 1.5
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Fig. 3: Representative chromatogram of mixed standard solution for system suitability
Fig. 4: A representative chromatogram of swab interference
Fig. 5: Calibration curve for rosuvastatin
Fig. 6: Calibration curve for aspirin
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Table 7: Results of robustness
Parameters Level Rosuvastatin Aspirin
R.T. (min) %RSD Tailing factor R.T. (min) %RSD Tailing factor
Change in mobile phase composition 45% of acetonitrile variation 6.0 1.1 1.20 3.2 1.5 1.16
50% of acetonitrile variation 4.99 1.01 1.09 2.99 0.84 1.11
55% of acetonitrile variation 4.82 0.1 1.87 2.83 1.2 0.83
Change in pH pH=2.3 2.92 0.1 1.7 4.82 0.7 1
pH=2.5 4.99 1.01 1.09 2.99 0.84 1.11
pH=2.7 2.98 0.5 1.15 4.95 1.7 1.08
Change in column oven temperature 25°C 4.99 1.01 1.09 2.99 0.84 1.11
30°C 4.89 0.7 1.17 2.94 1.1 0.95
Change in flow rate 1.3 ml/min 5.47 0.8 1.16 3.45 2.5 1.07
1.5 ml/min 2.99 1.01 1.09 4.99 0.84 1.11
1.7 ml/min 4.42 1.6 1.13 2.65 1.9 1.10
Table 6: Results of LOD and LOQ
Components LOQ LOD
Concentration, in µg/ml Concentration, in µg/ml
Rosuvastatin 0.1 0.03
Aspirin 0.1 0.03
LOD: Limit of detection, LOQ: Limit of quantitation
Table 4: Percentage recovery results of rosuvastatin and aspirin
Sample number 
(Swab number)
% recovery 100% level Acceptance 
criteria (%)Rosuvastatin Aspirin




Table 5: Results of precision













% RSD 0.76859 1.46886857
DISCUSSION
Preliminary experiments were carried out to achieve the best 
chromatographic conditions for the simultaneous determination of 
both the drugs. With the optimized chromatographic conditions, the 
HPLC instrument was subjected to system suitability. A representative 
chromatogram is depicted in Fig. 3. The system suitability parameters 
as summarized in Table 1, complied with the acceptance criteria. Hence, 
the system was found suitable for the analysis.
A representative chromatogram for swab interference is shown in 
Fig. 4. The chromatogram showed no interference at the retention time 
of the drugs. From the data tabulated in Table 2, none of the swabs 
showed interference. Hence, the method was found to be specific and 
the swabs were suitable for use.
The calibration curves (Figs. 5 and 6) showed a good correlation 
between peak areas and concentration of the drugs within the 
concentration range specified. The correlation coefficient (r2) values 
for both the drugs were >0.999. The linearity data are summarized in 
Table 3. The linearity range was thus established as 0.1–20 µg/ml for 
both the drugs.
The mean % recovery at 100% level as shown in Table 4 was in the 
range of 70.0–110.0%. Hence, the method was found to be accurate for 
both the drugs.
The results of precision study as depicted in Table 5 showed % RSD 
value for peak areas of both drugs <2.0%. Hence, the method was found 
to be precise at the LOQ level.
The calculated LOD and LOQ values are shown in Table 6, which proved 
that the method was sensitive for both the drugs.
For robustness study, it was observed that there were no marked 
changes in any of the tested method parameters, which demonstrated 
that the developed method was robust. The results of robustness study 
are summarized in Table 7.
CONCLUSION
A simple, novel, and economical reversed-phase high-performance 
liquid chromatography method for cleaning validation has been 
developed for the simultaneous estimation of rosuvastatin and aspirin. 
The method was validated as per ICH guidelines for specificity, linearity, 
accuracy, precision, and robustness. The developed method is thus a 
sensitive analytical tool for ensuring the effectiveness of the cleaning 
procedure adopted.
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